Details der Publikation - A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma : AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TOEVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135)MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUSDARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTSWITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVERECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDINGLENALIDOMIDE AND A PROTEASOME INHIBITOR

Medienart:	Klinische Studie

Erscheinungsjahr:	2022
Erschienen:	2022

Enthalten in:	WHO International Clinical Trials Registry Platform - (2022) vom: 19. Apr. Zur Gesamtaufnahme - year:2022

Sprache:	Unbestimmt

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: MULTIPLE MYELOMA MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 12-07-2021, Last updated: 2022-11-24

ICTRP ID:	EUCTR2021-000044-22-SE C1071005 NCT05020236

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	WHO008081506

Internformat


LEADER	01000caa a22002652 4500
001	WHO008081506
003	DE-627
005	20230425170335.0
007	cr uuu---uuuuu
008	211222s2022 xx \|\|\|\|\|o 00\| \|\|und c
035			\|a (DE-627)WHO008081506
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2021-000044-22-SE
035			\|a (UBBS_Klinische_Studien_WHO)C1071005
035			\|a (UBBS_Klinische_Studien_WHO)NCT05020236
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a und
245	1	0	\|a A Phase 3 Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma \|b AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TOEVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135)MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUSDARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTSWITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVERECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDINGLENALIDOMIDE AND A PROTEASOME INHIBITOR
264		1	\|c 2022
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 12-07-2021, Last updated: 2022-11-24
650		4	\|a Medical Condition: MULTIPLE MYELOMA MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2022) vom: 19. Apr.
773	1	8	\|g year:2022 \|g day:19 \|g month:04
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2021-000044-22 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2022 \|b 19 \|c 04

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände